# US 2018/0022786 A1 · Novel sodium channel blocking peptides and the use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022786 A1
- Document ID: US20180022786A1
- Status: Published application
- Kind: A1
- Application number: 15/649,922
- Filed: 2017-07-14
- Published: 2018-01-25
- Earliest claimed: 2012-07-27
- Assignees: Purdue Pharma L.P.
- Applicants: Purdue Pharma L.P.
- Inventors: Donald James Kyle; Jae Hyun Park
- Web page: https://patentgrep.com/patent/US20180022786A1

## CPC

- C07K 14/43518: {from spiders}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to C-terminal modified Protoxin II peptides that selectively inhibit the Nav1.7 sodium channel; the present invention also relates to pharmaceutical compositions useful for prophylactic or therapeutic treatment of a disorder responsive to the blockade of sodium ion channels, especially Nav1.7 sodium ion channels; the present invention further provides methods of treating a disorder responsive to the blockade of sodium channels, and particularly Nav1.7 sodium channels, in a mammal sulfuring from excess activity of said channels.

## Claims

### Claim 1

A C-terminal modified Protoxin II peptide of general formula (I):
wherein:
Pro is Protoxin II of the amino acid sequence: Tyr1-Cys2-Gln3-Lys4-Trp5-Met6-Trp7-Thr8-Cys9-Asp10-Ser11-Glu12-Arg13-Lys14-Cys15-Cys16-Glu17-Gly18-Met19-Val20-Cys21-Arg22-Leu23-Trp24-Cys25-Lys26-Lys27-Lys28-Leu29-Trp30 (SEQ ID NO: 1),
wherein Trp30 is D or L—Trp30,
X is —O—,
R1 is C1-C6 alkyl, or C3-C7 cycloalkyl or C5-C10 aryl;
or a pharmaceutically acceptable salt, prodrug or solvate thereof.

### Claim 2 (depends on 1)

The peptide of claim 1 or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Trp30 is L-Trp.

### Claim 3 (depends on 1)

The peptide of claim 1 or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Trp30 is D-Trp.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The peptide of claim 1 or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein X is —O—.

### Claim 6 (depends on 1)

The peptide of claim 1 or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein R1 is C1-C4 alkyl.

### Claim 7 (depends on 1)

The peptide of claim 1 or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein R1 is methyl, ethyl or propyl.

### Claim 8 (depends on 1)

The peptide of claim 1 or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein R1 is methyl.

### Claim 9 (depends on 1)

The peptide of claim 1 or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein R1 is cyclopentyl, cyclohexyl or cycloheptanyl.

### Claim 10 (depends on 1)

The peptide of claim 1 or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein R1 is cyclohexyl.

### Claim 11 (depends on 1)

The peptide of claim 1 or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein R1 is C5 or C6 aryl.

### Claim 12 (depends on 1)

The peptide of claim 1 or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein R1 is phenyl.

### Claim 13 (depends on 1)

The peptide of claim 1 or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein R1 is a group of the following formula:

### Claim 14 (depends on 1)

The peptide of claim 1 or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein each of Trp30, X and R1 is listed in the following table:
C-Modified Protoxin
II Peptide
SEQ ID NO:
Trp30
X
R1
Protoxin II-OMe
12
L-Trp30
—O—
—CH3

### Claim 15 (depends on 1)

The peptide of claim 1 or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein said peptide has a higher potency to Nav1.7 as compared to unmodified Protoxin II measured by Fluorometric Imaging Plate Reader Assays or Electrophysiology Assay.

### Claim 16 (depends on 1)

A pharmaceutical composition, comprising at least one C-terminal modified Protoxin II peptide of claim 1 or a pharmaceutically acceptable salt, prodrug or solvate thereof, and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 1)

A method of prophylactically or therapeutically treating pain, comprising administering an effective amount of at least one C-terminal modified Protoxin II peptide of claim 1 or a pharmaceutically acceptable salt, prodrug or solvate thereof, to a subject in need thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein said pain is neuropathic pain, chronic pain, acute pain, inflammatory pain, or surgical pain.

### Claim at position 19

19-22. (canceled)

### Claim 23 (depends on 1)

A method of selectively blocking sodium channel Nav1.7 in a cell, comprising contacting a cell expressing Nav1.7 with at least one C-terminal modified Protoxin II peptide of claim 1, or a pharmaceutically acceptable salt, prodrug or solvate thereof.

### Claim 24

(canceled)

### Claim 25 (depends on 1)

A method of modulating the activity of sodium channel Nav1.7 in a cell, or in a membrane preparation, comprising contacting said cell or said membrane preparation with an effective amount of at least one C-terminal modified Protoxin II peptide of claim 1, or a pharmaceutically acceptable salt, prodrug or solvate thereof.

### Claim 26

(canceled)
